Adding Zytiga and Prednisone to Regimen Is Effective in Treating High-Risk Prostate Cancer, Study Finds

Adding Zytiga and Prednisone to Regimen Is Effective in Treating High-Risk Prostate Cancer, Study Finds
Adding Zytiga (abiraterone acetate) plus prednisone to a regimen of radiotherapy and androgen deprivation therapy is effective in treating patients with high-risk prostate cancer, a Phase 2 clinical trial shows. The combination allows researchers to lower the duration of androgen deprivation therapy (ADT), which is associated with significantly increased toxicity when used long-term. The results were

Knowledge is power when living with prostate cancer.

Get access to the web’s leading Prostate Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *